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KSHV and Kaposi's Sarcoma: Minireview
The End of the Beginning?
common in HIV-positive gay men than in other groups
who acquire HIV by nonsexual routes (e.g., hemophili-
acs). These and other data suggest that another agent
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Enter KSHV
Motivated by these considerations, Chang et al. (1994)
searched for DNA sequences that were present in KS
It is now nearly three years since the seminal identifica-
lesions and absent in uninvolved tissues. This search
tion of the genome of a novel human herpesvirus in
yielded two small fragments of DNA that showed clear
Kaposi's sarcoma (KS) specimens by Yuan Chang and
homology to known herpesvirus sequences. From these
colleagues (Chang et al., 1994). This discovery changed starting bits of DNA, the whole 170 kb genome has
the face of KS research and ignited a passionate debate now been cloned in several laboratories; the complete
about the role of this agent in the etiology of the tumor.
sequence of one isolate has been published (Russo et
Since then, progress in both laboratory and clinical in-
al., 1996) and that of a second is nearing completion
vestigation has been swift, and both lines of work are (see Niepel et al., 1997). The sequence reveals KSHV
converging on theview that the KS-associated herpesvi- to be a member of the herpes family's lymphotropic
rus (KSHV; also known by its formal taxonomic designa- subgroup, whose best-known member is Epstein-Barr
tion as human herpesvirus 8) plays a critical role in the virus (EBV).
development of this neoplasm. Here we summarize the Not long after the first sighting of the genome, a B
evidence linking virus and disease and consider some cell line (BCBL-1) was identified in which the KSHV ge-
of the molecular mechanisms that might underly this nome is present in a latent state; treatment of these cells
association. with phorbol esters induces dramatic lytic replication
Backdrop: KS Epidemiology and Pathogenesis (Renne et al., 1996). This and subsequently identified
KS is a peculiar neoplasm that differs from more com- similar lines allow high-level virus production, examina-
mon tumors in many respects. Histologically, the lesions tion of the activity of antiviral drugs, and experimental
contain many different cell types, with the dominant access to the molecular biology of both latent and lytic
cell being the so-called spindle cell, thought to be of infection. In addition, such lines have also served as
endothelial origin. In addition, the tumors contain infil- sources of viral antigens for use in seroepidemiologic
trating inflammatory cells as well as a profusion of highly studies. Virus from these lines and from primary KS
characteristic neovascular elements. In immunocompe- specimens can be transmitted to several other cultured
tent hosts, KS is an indolent, largely local process, prop- cell lines, but this transmission is extremely inefficient
erties suggestive of a low malignant potential. While (cf. Foreman et al., 1997). Passage to animal hosts has
often more widespread in immunosuppressed hosts, in been similarly difficult: virus from BCBL-1 cells can be
whom it can be disfiguring or even fatal, even partial transmitted to Rhesus macaques, but again infection
restoration of immune competence can result in arrest occurs at an exceedingly low level and no disease is
(and sometimes remission) of the diseaseÐagain distin- induced in the recipients.
guishing it from more aggressive neoplasms. PCR-based studies on human tissues show that viral
Much of what we know about the histogenesis of KS genomes are found invirtually all KS tumors, irrespective
we owe to pioneering studies by Gallo and colleagues, of the stage of the lesion or the presence or absence
who first developed reproducible systems for the culti- of HIV. KSHV genomes have also been strongly linked
vation of spindle-like cells and established that these to several other proliferative lesions: certain AIDS-
cells, while not fully transformed, elaborate a variety of related B cell lymphomas (these tumors were in fact the
proinflammatory and angiogenic factors (reviewed in source of the B cell lines described above) and a rare
Ensoli et al., 1991). Based on these and other in vitro lymphoproliferative process called Castleman's disease
studies, it is now believed that spindle cells are the (Cesarman et al., 1995; Soulier et al., 1995). More recent
driving force of KS pathogenesis, with their products studies have also proposed an indirect link with multiple
responsible for the recruitment of the remaining cell myeloma, though the tumor cells themselves appear to
types in a paracrine fashion. If so, then the key etiologic be virus-free (Rettig et al., 1997).
question is: what initiates and sustains spindle cell Unlike HIV, KSHV can directly infect the KS spindle
growth? cell: in situ hybridization studies show viral DNA and
The strong association of KS with AIDS naturally led transcripts in the vast majority of spindle cells in KS
to early efforts to link HIV to KS etiology. However, spin- lesions (Boshoff et al., 1995; Staskus et al., 1997). Analy-
dle cells are not infected with HIV, and epidemiologic sis of the patterns of viral transcription shows that, as
data suggest that HIV is unlikely to be the sole factor expected, most such cells are latently infected. How-
in KS development (Beral et al., 1990). HIV-negative KS, ever, in AIDS-KS patients ca. 1%±5% of spindle cells
while rare in the West, is common in Africa and long appear to be supporting the lytic cycle (Staskus et al.,
antedated the AIDS epidemic there. Moreover, even 1997). In 30%±50% of AIDS-KS patients, viral DNA is
among US and European AIDS patients KS is not uni- also found in circulating B cells (Whitby et al., 1995).
Infected AIDS patients frequently display virions in theirformly distributed: the disease is 7- to 15-fold more
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Figure 1. Schematic Depiction of the Ge-
nome of KSHV and Related Herpesviruses
Conserved coding regions, largely encoding
lytic cycle genes, are shown in solid boxes.
Genes unique to each virus areshown in open
boxes; ORFs starting with S are largely
unique to HVS; those beginning with K largely
unique to KSHV. (This figure is modified from
Virgin et al., 1997, with the authors' per-
mission.)
saliva (Koelle et al., 1997), suggesting the possibility of infection to be more common in groups at high KS risk
than in those at lower risk.productive infection in salivary glands and/or pharygeal
lymphoid or epithelial tissue; the epidemiologic signifi- Thus, by every available criterion, KSHV appears to be
the agent predicted by the epidemiology of KS: infectioncance of such virus, however, is uncertain. Virus is only
occasionally found in semen, though such shedding precedes development of the tumor, tracks tightly with
KS risk, and specifically targets the cell thought to bemay be low-level and intermittent.
Epidemiologic Studies Strengthen the Link at the heart of the lesion. This is a very strong case, and
most workers in the field now firmly believe that KSHVThe above studies locate KSHV squarely at the scene
of the crime, but (as students of Perry Mason and O. J. is necessary for KS development. Formally, further evi-
dence in favor of this could come from either transmis-Simpson well know) such information does not suffice
to achieve a conviction. Further incriminating evidence, sion of both infection and disease to a suitable animal
or demonstration that a specific intervention (e.g., vacci-however, has been forthcoming from seroepidemiologic
studies. A variety of serolgic tests for KSHV infection nation) that blocks infection reduces the incidence of
the disease in man, but neither result is just around thehave been developed (see Ganem, 1996, for references
and review). Most involve detection of a latency-associ- corner.
But is KSHV sufficient for KS development? Almostated nuclear antigen (LANA) present in infected B cell
cultures; other tests have examined reactivity to lytic- assuredly not. Recall that at least 1%±2% of the general
population is seropositive, indicating past exposure andcycle antigens. The tests for anti-LANA are highly spe-
cific but only about 80% sensitive for detection of infec- ongoing latency in at least some cells of the host. Since
these individuals have no measureable risk of KS, othertion in KS patients, so prevalence figures based on this
test must be considered minimal estimates. Around cofactors must be involved, of which HIV infection is the
most obvious and (quantitatively) the most important.1%±2% of healthy, HIV-negative US blood donors are
positive for anti-LANA; by contrast, 25%±30% of HIV- Deciphering exactly how HIV exerts its effects contin-
ues to represent a major charge to the fieldÐand onepositive gay men are seropositive in this test. Remark-
ably, HIV-positive groups known to be at lower risk for that, lamentably, has been somewhat underemphasized
lately in the face of the explosion of interest in KSHV.KS have dramatically lower rates of anti-LANA positivity:
2%±3% of hemophiliacs, 3%±4% of HIV-positive wo- The immune deficiency induced by HIV is surely one
contributing factor here, but it remains to be seen if HIVmen. These numbers are strikingly similar to the preva-
lences of KS in AIDS patients from such groups. Al- gene products make a more specific contribution to KS
pathogenesis.though data on vertical transmission are very limited,
they likewise are in accord with the known low preva- The KSHV Sequence: A Provocative Harvest,
but Can We Yet Tell the Wheatlence of KS in pediatric AIDS. By contrast, anti-LANA
prevalences are high in Africa, where endemic KS has from the Chaff?
The upcoming chapter in KSHV research, which beganbeen known to exist for many years. Thus, at the popula-
tion level there is a strong linkage of KSHV infection with the publication of the viral genomic sequence,
promises to be a page-turner. The sequence, as ex-with KS risk.
This is not to imply that KSHV seroepidemiology is pected, contains the usual complement of lytic-cycle
genes: structural proteins, enzymes involved in DNAwithout controversy. While the use of several different
tests for antibodies to lytic antigens has yielded preva- synthesis, etc. As depicted in Figure 1, these conserved
genes are arrayed in several blocks; flanking them arelence estimates similar to those revealed by anti-LANA
testing, one study (Lennette et al., 1996) has suggested clusters of novel open reading frames, most of which
are not found in previously described herpesviruses. Atthat anti-lytic cycle antibodies might be present in a
much higher fraction of the population: up to 25% of present there are at least 15 such genes unique to KSHV,
designated simply as open reading frames (ORFs) K1±HIV-negative donors, and virtually all HIV-positive gay
men. Even this study, however, consistently found KSHV 15; a few other genes of this class are shared only with
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Table 1. Selected Accessory Genes of KSHV
Viral Gene Cellular Homolog Putative Function
K1 Ð signaling; growth control?
4 CD46, CR1,2 complement regulation
K2 IL6 paracrine signaling
K4 CC chemokines paracrine signaling regulation
K6 CC chemokines paracrine signaling?
16 bcl-2 regulation of apoptosis
K9 IRF-1 gene regulation; growth control?
K12 Ð latent membrane protein?
71 DED domain proteins regulation of apoptosis
72 cyclin D growth control?
73 Ð LANA; transcription factor?
74 CXC chemokine receptor signaling
K14 OX2 cell±cell interaction?
its closest relative, herpesvirus saimiri (HVS), a simian signals. On the other hand, plausible roles in the lytic
cycle for many of the genes in Table 1 can be readilyT-lymphotropic agent. Notably, none of the genes
envisioned: viral inhibitors of apoptosis, for example,known to be expressed in EBV latency have homologs
may be required to prevent premature host cell deathin KSHV: the latency program of KSHV is therefore a
until the virus can complete its lytic cycle. So the se-tabula rasa that will have to be filled in by direct exper-
quence should serve as a stimulus and not as a substi-iment.
tute for the next, less glamorous phase of KSHV re-Table 1 lists some of these accessory genes and sum-
search: the enumeration and characterization of the viralmarizes key features gleaned from their sequence. The
genes expressed in latency.most striking feature of the list is the preponderance of
Already there has been excellent headway made here.homologs of cellular genes, including host genes known
The most abundant latent transcript harbors a 60 codonto function in cell cycle regulation (cyclin D), control of
open reading frame (ORF K12) that could encode anapoptosis (bcl-2), cell±cell interaction (OX2, an immuno-
extremely hydrophobic small polypeptide of as-yet-globulin superfamily member), immunoregulation (com-
unknown function. LANA, the latent nuclear antigen soplement control proteins), and cytokine signaling (CC
useful in serologic work, has been identified in severalchemokines, IL6, CXC chemokine receptors, interferon-
labs as the product of ORF 73; its sequence suggestsregulatory factor 1). Many of these viral genes have been
that it may represent a transcription factor. Of the genesshown to encode proteins that preserve the functions
in Table 1 that have cellular homologs, only that for ORFpredicted by their homologies: for example, ORF 72, the
72 (v-cyclin) is known to be expressed in latency, thoughviral cyclin, can bind and activate cdk-6; ORF 16, the
many of the others have not yet been closely examinedviral bcl-2 analog, can block experimental apoptosis;
and may yet qualify.and ORF K2, the viral IL6 homolog, can support the
Another approach to the identification of genes thatsurvival of IL6-dependent cell lines (see Moore et al.,
may relate to KS pathogenesis has been the search1996, and Niepel et al., 1997, for references). Sometimes
for genes that promote growth deregulation in culturedthe viral products display unexpected activities: for ex-
fibroblasts or other heterologous model systems. To
ample, the virus-encoded chemokine receptor homolog
date, such work, now ongoing in several laboratories,
(ORF 74) appears to be constitutively active, signaling
has fingered additional suspects from the list in Table
even in the absence of exogenous ligands (Arvanitakis
1, and efforts are underway to determine the signifi-
et al., 1997), while one of the chemokine homologs (ORF
cance of these findings for tumorigenesis in vivo. It will
K4) appears to be able to function as an antagonist of
be important to determine, for example, whether any of
chemokine signaling (Kledal et al., 1997). these genes are expressed in latently infected KS spin-
The existence of virally encoded cytokines and cyto- dle cells. Even assuming that they are, it is not clear how
kine receptor genes in a tumor in which paracrine signal- to relate overt cell transformation in these heterologous
ing has long been suspected is particularly provocative. systems to the rather more subtle growth deregulation
But we are deeply in the dark as to whether and how of spindle cells in a KS tumor. Perhaps the latter is the
such genes might function during pathogenesis, and result of low-level expresssion of these genes or their
the temptation to jump to facile conclusions should be modulation by other viral or host genes. Or perhaps
resisted. For example, the patterns of expression of these genes relate not to KS but to the rarer, more overt
some of these genes (e.g. ORFs K4 and 6) suggest that lymphoid malignancies also linked to KSHV. Time will
they may be expressed primarily in the lytic cycle rather tell, but one could not imagine a more promising start
than in latency, and it is latency-associated genes that for this line of inquiry.
are primarily responsible for tumorigenesis in other on- Perspective
cogenic herpesviruses. Is it possible that lytically in- The rapid pace of progress in KSHV research in its first
fected cells might elaborate factors that support tumori- 3 years has given us a broad overview of the biology
genesis by surrounding cells? Perhaps, but this model of the virus and generated the experimental systems
is complicated by the fact that most surrounding spindle necessary for a concerted molecularattack on its patho-
cells are latently infected, seemingly implying that la- genetic mechanisms. The year 1997 thus marks an im-
portant way station in the evolution of the field: intency itself might be required for receptivity to such
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Whitby, D., Howard, M., Tenant-Flowers, M., Brink, N., Copas, A.,Churchill's memorable phrase, we have arrived at the
Boshoff, C., Hatziannou, T., Suggett, F., Aldam, D., Denton, A., etend of the beginning. Now comes the spade work: for
al. (1995). Lancet 346, 799±802.the virologist, this means enumerating the latent genes,
working out the biochemical activities of their products,
developing better systems for infectivity testing, and
characterizing thedeterminants of immunity. Major chal-
lenges here will be to determine whether the latency
program in B cells differs from that in KS spindle cells
and whether any of the products of the lytic cycle can
also influence the growth of latently infected or unin-
fected cells. For the clinical investigator, it means defin-
ing more precisely the routes of transmission and de-
termining whether any other clinical syndromes are
attributable to infection. Detail work, to be sure, but, as
Mies van der Rohe famously noted, God dwells in the
details. Given the highly unusual biology of KS, it is likely
that the details of KSHV pathogenesis will conform only
loosely to other precedents in viral oncology and may
well suggest entirely novel mechanisms that could form
the basis for new treatment or prevention strategies for
KSHV-associated diseases.
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